At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 120 enrolled
Drug / intervention
Aesculus hippocastanum, and associationsdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Clinical Study of Non-inferiority Between Aesculus Hippocastanum 50mg, Polygonum Acre 10mg, Smilax Pepyracea 40mg, Rutin 20mg Versus Diosmin 450mg and Hesperidin 50mg Tablets in Chronic Venous Insufficiency After 3 Months of Therapy
In Brief
A Phase 4 clinical trial evaluating Aesculus hippocastanum, and associations for Chronic Venous Insufficiency. Completed, enrolled 120 participants across 1 site.
Detailed Summary
To demonstrate the clinical non-inferiority of efficacy between Aesculus hippocastanum, Polygonum acre, Smilax Pepyracea, Rutin and Diosmin 450mg and Hesperidin 50mg tablets in the improvement of lower limb symptoms assessed by means of a 100mm visual scale (VAS) over 3 months among adult patients presenting with chronic venous insufficiency of the lower limbs.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Venous Insufficiency
CountriesBrazil
Collaborators--
Timeline
Phase 4CompletedFinished
20252026
First PostedAug 2024
Enrollment StartNov 2024
Primary CompletionMay 2025
Study CompletionJun 2025
TodayJul 2026
First PostedAug 30, 2024
Enrollment StartNov 6, 2024
Primary CompletionMay 5, 2025
Study CompletionJun 11, 2025
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 1.8 years ago
Interventions
Aesculus hippocastanum, and associationsdrug
combination product